Latest Financial Results
Q1 2021
Quarterly Results
March 31, 2021
Stock Quote
Titan Pharmaceuticals, Inc.
Nasdaq: TTNP
Volume
Day Low/High
52 Week Low/High
Company Overview
Titan is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides the potential for an efficacy and/or safety benefit. Titan's lead product in development is an implant for the treatment of moderate-to severe-chronic pruritus.
Officers & Directors
Marc Rubin, MD
Executive Chairman
Dr. Rubin has served as Titan's Executive Chairman of the Board of Directors since 2009, after previously holding the position of CEO. Prior to joining Titan, Dr. Rubin was Head of Global Research and Development for Bayer Schering Pharma,…
View Full Bio
Kate Beebe DeVarney, Ph.D.
President and Chief Operating Officer
Dr. DeVarney has served as a Director of Titan’s Board of Directors since 2019 and in October 2020, she became Titan’s President and Chief Operating Officer. She previously served as Chief Scientific Officer and has been with the…
View Full Bio
Marc Rubin, MD
Executive Chairman
Dr. Rubin has served as Titan's Executive Chairman of the Board of Directors since 2009, after previously holding the position of CEO. Prior to joining Titan, Dr. Rubin was Head of Global Research and Development for Bayer Schering Pharma,…
View Full Bio
Kate Beebe DeVarney, Ph.D.
President and Chief Operating Officer
Dr. DeVarney has served as a Director of Titan’s Board of Directors since 2019 and in October 2020, she became Titan’s President and Chief Operating Officer. She previously served as Chief Scientific Officer and has been with the…
View Full Bio
Joseph A. Akers
Audit Committee
Mr. Akers has served as president of Bayer's hematology/cardiology business, where he oversaw the core of Bayer's specialty pharmaceuticals development, with significant products in hematology and specialty cardiology. Mr. Akers also…
View Full Bio
M. David MacFarlane, PhD
Audit Committee; Corporate Governance and Nominating Committee
Dr. MacFarlane has been a Director of Titan Pharmaceuticals since May 2002. Dr. MacFarlane served as Vice President and Responsible Head of Regulatory Affairs of Genentech, Inc. from 1989 until his retirement in August 1999. Prior to…
View Full Bio
James R. McNab, Jr.
Corporate Governance and Nominating Committee
Mr. McNab, an entrepreneur experienced in building and growing companies, is co-founder and chairman of Curis, a publicly traded oncology company that partnered with Roche to develop and commercialize a first-in-class hedgehog inhibitor…
View Full Bio